Promising Phase III Results for Amgen Ovarian Cancer Candidate
Announcing top-line results from its Phase III TRINOVA-1 trial evaluating trebananib plus paclitaxel vs. placebo plus paclitaxel in recurrent ovarian cancer, Amgen today said its drug had met its primary endpoint of progression-free survival.
The firm observed a 34% reduction in the risk of disease progression or death in patients given trebananib plus paclitaxel, compared with placebo.
Overall, median progression-free survival was 7.2 months with trebananib arm vs. four months in the control arm, Amgen said, noting it expects to report overall survival results in 2014.
"Angiopoietin inhibition has been a focus of research at Amgen and these results suggest that the novel biology of trebananib may offer a promising approach for patients with ovarian cancer,” Sean E. Harper, M.D., evp of R&D at Amgen said in a statement.